Please ensure Javascript is enabled for purposes of website accessibility

Why General Electric Stock Popped 15% This Morning

By Rich Smith – Updated Apr 15, 2019 at 2:53PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

GE's CEO just had a bright idea about who to sell his healthcare unit to.

What happened

Four months ago, General Electric (GE -3.03%) dropped a bombshell: John Flannery was out, and former Danaher (DHR -2.20%) CEO H. Lawrence Culp, Jr., was in as GE's new CEO. Four months later, GE has just dropped another bombshell, and it's being even better received:

This morning, General Electric announced that it has reached a "definitive agreement" to sell its BioPharma business to Danaher -- GE's CEO's old shop -- and GE will receive $21.4 billion in return.

GE stock leapt 15.5% in early Monday trading on the news and remains up 8.8% as of 11:40 a.m. EST.

Man with idea light bulb containing dollar sign over his head.

GE's CEO just had a bright idea about who to sell his healthcare unit to. Image source: Getty Images.

So what

GE's press release contains the details: Danaher will buy GE BioPharma for $21 billion, cash, plus assumption of "certain pension liabilities" -- worth $400 million. With GE BioPharma having produced $3 billion in 2018 revenues, the valuation of this deal, at a hair over 7 times sales, looks like great news for GE, whose own stock commands a valuation of less than 0.8 times sales.

GE Healthcare President Kieran Murphy opined that while "the BioPharma business has been a strong contributor to our success" at GE, he is also "confident this agreement represents a great opportunity for our valued colleagues to flourish under the ownership of Danaher."

Investors apparently agree, as Danaher stock -- which had gained 7.8% by 11:40 a.m. EST -- is going up in tandem with GE's. And given GE's CEO's close familiarity with both companies and presumed warm feelings for his old place of employ, it makes sense that this deal would appeal to both buyer and seller.

Check out the latest GE earnings call transcript.

Now what

GE's decision to sell GE BioPharma to its CEO's old company may raise eyebrows among investors. Indeed, I see there are at least a couple of law firms reminding investors of ongoing shareholder class action suits against GE today. Still, management at GE thinks it should be able to clear all hurdles and close this sale by the end of the year.

Then, with $21 billion worth of new cash in hand, GE can set about using "the proceeds from the transaction to reduce leverage and strengthen its balance sheet." With $110 billion in debt to address, it should have no difficulty finding loans to pay off.

Rich Smith has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

General Electric Stock Quote
General Electric
GE
$85.47 (-3.03%) $-2.67
Danaher Stock Quote
Danaher
DHR
$261.16 (-2.20%) $-5.88

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.